[{"address1": "245 Main Street", "address2": "Second Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 500 8080", "website": "https://immuneering.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Benjamin J. Zeskind M.B.A., Ph.D.", "age": 40, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 935085, "exercisedValue": 0, "unexercisedValue": 1146738}, {"maxAge": 1, "name": "Mr. Robert J. Carpenter M.B.A., M.S.", "age": 77, "title": "Co-Founder & Chair Emeritus", "yearBorn": 1946, "fiscalYear": 2023, "totalPay": 75357, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brett M. Hall Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 905415, "exercisedValue": 0, "unexercisedValue": 1402731}, {"maxAge": 1, "name": "Mr. Harold E. Brakewood", "age": 57, "title": "Chief Business Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 579769, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Paula  George CPA", "title": "Director of Accounting & Operations and Assistant Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael D. Bookman J.D.", "age": 36, "title": "Chief Legal Officer & Secretary", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leah R. Neufeld", "age": 50, "title": "Chief People Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  King Ph.D.", "title": "Head of Discovery & VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Praveen  Nair Ph.D.", "title": "Head of Translational Pharmacology & VP", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  Sebastian CPA", "title": "Executive Director & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 7, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1714348800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.48, "open": 1.49, "dayLow": 1.39, "dayHigh": 1.575, "regularMarketPreviousClose": 1.48, "regularMarketOpen": 1.49, "regularMarketDayLow": 1.39, "regularMarketDayHigh": 1.575, "beta": -0.894, "forwardPE": -0.7395833, "volume": 560629, "regularMarketVolume": 560629, "averageVolume": 747152, "averageVolume10days": 397040, "averageDailyVolume10Day": 397040, "bid": 1.37, "ask": 1.47, "bidSize": 100, "askSize": 100, "marketCap": 42107828, "fiftyTwoWeekLow": 1.38, "fiftyTwoWeekHigh": 11.92, "fiftyDayAverage": 3.5633, "twoHundredDayAverage": 6.474625, "currency": "USD", "enterpriseValue": -39620480, "floatShares": 17002161, "sharesOutstanding": 29653400, "sharesShort": 2730363, "sharesShortPriorMonth": 2610384, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0932, "heldPercentInsiders": 0.29177, "heldPercentInstitutions": 0.38021, "shortRatio": 1.75, "shortPercentOfFloat": 0.1741, "impliedSharesOutstanding": 29653400, "bookValue": 3.094, "priceToBook": 0.45895278, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -53471624, "trailingEps": -1.88, "forwardEps": -1.92, "enterpriseToEbitda": 0.682, "52WeekChange": -0.8386364, "SandP52WeekChange": 0.23099434, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "IMRX", "underlyingSymbol": "IMRX", "shortName": "Immuneering Corporation", "longName": "Immuneering Corporation", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e5829551-96d1-35fc-9c6d-d258079bf8f6", "messageBoardId": "finmb_308350677", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.42, "targetHighPrice": 25.0, "targetLowPrice": 3.0, "targetMeanPrice": 13.29, "targetMedianPrice": 15.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 85665688, "totalCashPerShare": 2.925, "ebitda": -58060804, "totalDebt": 4462959, "quickRatio": 10.919, "currentRatio": 11.355, "debtToEquity": 4.927, "returnOnAssets": -0.32459, "returnOnEquity": -0.53358, "freeCashflow": -31097564, "operatingCashflow": -48968632, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]